Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
10963593 | Vaccine | 2015 | 7 Pages |
Abstract
Participants were randomised to IM or SC administration (1:1). The baseline demographics were comparable between groups; mean age: 62.6 years (range: 50.0-90.5). The primary immunogenicity objectives were met (per protocol analysis): GMT ratio (IM/SC): 1.05 (95% CI: 0.93-1.18); GMFR: 2.7 (2.4-3.0). VZV immune response using IFN-γ ELISPOT were comparable between groups. Frequencies of systemic adverse events were comparable between groups. Injection-site reactions were less frequent with IM than SC route: erythema (15.9% versus 52.5%), pain (25.6% versus 39.5%) and swelling (13.6% versus 37.3%), respectively. In adults aged â¥50 years, IM administration of Zostavax elicited similar immune responses to SC administration and was well tolerated, with fewer injection-site reactions than with SC administration.
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Javier Diez-Domingo, Thomas Weinke, Juan Garcia de Lomas, Claudius U. Meyer, Isabelle Bertrand, Cécile Eymin, Stéphane Thomas, Christine Sadorge,